Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 640 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Transfusion Clear all
Terminated Phase 2 Interventional Results available

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

NCT02943668
View directory record Official record
Conditions
Anemia, Myelodysplastic Syndrome
Interventions
Deferasirox, Laboratory Biomarker Analysis
Drug · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Not applicable Interventional

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

NCT02179359
View directory record Official record
Conditions
Sickle Cell Disease, Transfusion Dependent Alpha- or Beta- Thalassemia, Diamond Blackfan Anemia, Paroxysmal Nocturnal Hemoglobinuria, Glanzmann Thrombasthenia, Severe Congenital Neutropenia, Shwachman-Diamond Syndrome, Non-Malignant Hematologic Disorders
Interventions
Reduced Toxicity Ablative Regimen, Reduced Intensity Preparative Regimen, Myeloablative Preparative Regimen
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 55 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2025 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

Epoetin Alfa in Treating Anemia in Patients Undergoing Chemotherapy for Multiple Myeloma

NCT00400686
View directory record Official record
Conditions
Anemia, Multiple Myeloma, Plasma Cell Neoplasm
Interventions
epoetin alfa
Biological
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 23, 2026, 2:15 AM EDT
Withdrawn No phase listed Observational

Detailed Evaluation of Microchimerism

NCT01094197
View directory record Official record
Conditions
Chimerism, Blood Transfusion, Wounds and Injuries, Hematopoiesis
Interventions
Not listed
Lead sponsor
Vitalant Research Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 12, 2013 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Early Phase 1 Interventional

TPO-Mimetic Use in Children for Hematopoietic Failure

NCT04478227
View directory record Official record
Conditions
Bone Marrow Failure Disorders, Aplastic Anemia, Thrombocytopenia, Refractory Cytopenia of Childhood, Myelodysplastic Syndrome(MDS)
Interventions
Romiplostim
Drug
Lead sponsor
Anjali Sharathkumar
Other
Eligibility
0 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 3 Interventional

Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

NCT00112983
View directory record Official record
Conditions
Leukemia
Interventions
eculizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 30, 2013 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Results available

Immunomodulation Following Transfusion

NCT00810810
View directory record Official record
Conditions
Blood Component Transfusion
Interventions
Standard blood components, Leukoreduced blood components, Leukoreduced and irradiated
Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 26, 2017 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Deferasirox in Non-transfusion Dependent Thalassemia Patients With Iron Overload and a One Year Open-label Extension Study

NCT00873041
View directory record Official record
Conditions
Non-transfusion Dependent Thalassemia
Interventions
deferasirox, placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
10 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 9, 2013 · Synced Oct 23, 2026, 2:15 AM EDT
Completed No phase listed Observational

Study of Transfusion-Transmitted Infections

NCT00023023
View directory record Official record
Conditions
Viral Disease, Blood Donation, Transfusion-Transmitted Infections
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
1,771 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Not applicable Interventional Results available

Effects of Exercise in Combination With Epoetin Alfa

NCT00577096
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Epoetin Alfa, Exercise, Autologous Peripheral Blood Stem Cell Transplantation, Red Blood Cell Transfusion, Thalidomide, Heparin, Low-Molecular-Weight, Platelet Transfusion, Melphalan, Total Therapy II
Drug · Behavioral · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Oct 23, 2026, 2:15 AM EDT
Withdrawn Early Phase 1 Interventional

Utilization of Donor Whole Blood for Blood Transfusion in Deceased Donor Liver Transplantation

NCT04383756
View directory record Official record
Conditions
Transfusion Related Complication, Liver Transplant
Interventions
Donor Blood, Banked Blood
Biological
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 4 Interventional Results available

Palatability and Tolerability of Deferasirox Taken With Meals, With Different Liquids or Crushed and Added to Food

NCT00845871
View directory record Official record
Conditions
Transfusional Hemosiderosis
Interventions
deferasirox:
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
23
States / cities
Oakland, California • Palo Alto, California • Pleasant Hill, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2021 · Synced Oct 23, 2026, 2:15 AM EDT
Completed No phase listed Observational

Coagulation Test Changes Associated With Acute Normovolemic Hemodilution in Cardiac Surgery

NCT03647644
View directory record Official record
Conditions
Coagulation Disorder, Bleeding
Interventions
Coagulation Laboratory Testing
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 3 Interventional

INTERCEPT Blood System for RBCs Study in Regions at Potential Risk for Zika Virus Transfusion-Transmitted Infections

NCT03037164
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT Blood System for Red Blood Cells, Conventional (Control)
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
4 Years and older
Enrollment
692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
12
States / cities
Phoenix, Arizona • New Haven, Connecticut • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Early Phase 1 Interventional

A Pilot Trial Using Isatuximab to Overcome Platelet Transfusion Refractoriness in Human Leukocyte Antigen Allo-Immunized Patients (SuppCare 001)

NCT05284032
View directory record Official record
Conditions
Platelet Refractoriness, Hematologic Malignancy
Interventions
isatuximab 10 mg/kg
Drug
Lead sponsor
Firas El Chaer, MD
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 31, 2024 · Synced Oct 23, 2026, 2:15 AM EDT
Recruiting Phase 3 Interventional

Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease

NCT05477563
View directory record Official record
Conditions
Beta-Thalassemia, Thalassemia, Hematologic Diseases, Genetic Diseases, Inborn, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Anemia
Interventions
CTX001
Biological
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years to 35 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
New York, New York • Charlotte, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Detecting Autologous Transfusion by Measuring Alterations in the Dynamics of Red Blood Cell Maturation and Recycling

NCT02684747
View directory record Official record
Conditions
Blood Transfusion, Autologous, Blood Doping
Interventions
Autologous Transfusion, Control - Normal Saline (Placebo)
Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 35 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Early Phase 1 Interventional Results available

COVID-19 Convalescent Plasma

NCT04340050
View directory record Official record
Conditions
Coronavirus
Interventions
anti-SARS-CoV-2 convalescent plasma
Biological
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 23, 2026, 2:15 AM EDT
Withdrawn Not applicable Interventional

Safety and Efficacy of Fetoscopes Used in Fetoscopic Selective Laser Photocoagulation

NCT06022510
View directory record Official record
Conditions
Twin Monochorionic Diamniotic Placenta
Interventions
Fetoscopy Sets for Anterior and Posterior Placentas
Device
Lead sponsor
Michael A Belfort
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Active, not recruiting Phase 3 Interventional Results available

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

NCT04717414
View directory record Official record
Conditions
Myeloproliferative Disorders, Myelofibrosis, Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Anemia
Interventions
ACE-536, Placebo
Drug · Other
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
313 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2032
U.S. locations
14
States / cities
Los Angeles, California • Orlando, Florida • Plantation, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 2:15 AM EDT
Completed No phase listed Observational Results available

Assessment of Pain in People With Thalassemia Who Are Treated With Regular Blood Transfusions

NCT00872833
View directory record Official record
Conditions
Thalassemia
Interventions
Not listed
Lead sponsor
Carelon Research
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Los Angeles, California • Oakland, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2015 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Not applicable Interventional Results available

Evaluating the Use of Thromboelastography (TEG) in Patient's Requiring Extracorporeal Membrane Oxygenation (ECMO)

NCT02887820
View directory record Official record
Conditions
Heart Disease, Lung Disease
Interventions
Thromboelastograph
Device
Lead sponsor
Stephen Esper
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 31, 2025 · Synced Oct 23, 2026, 2:15 AM EDT
Completed Phase 2 Interventional Results available

Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis

NCT01445769
View directory record Official record
Conditions
Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis
Interventions
Ruxolitinib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Highland, California • La Jolla, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2019 · Synced Oct 23, 2026, 2:15 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Oral TXA in Reducing Blood Loss and Transfusion in Hip Fractures

NCT02908516
View directory record Official record
Conditions
Hip Fractures, Blood Loss
Interventions
Tranexamic Acid, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 23, 2026, 2:15 AM EDT